RxDoctor Payments Data

Ranjana Nigalye, MD

Family Medicine · Brownwood, TXNPI 1477541886

Payments from drug & device makers

$1,275in general payments, 2019–2025

Across 71 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$229
  • AstraZeneca$155
  • AbbVie$124
  • Idorsia Pharmaceuticals US Inc$114
  • Pfizer$97
  • Mylan Specialty L.p.$94
  • plus $462 from 15 others

What the payments were for

  • Food & beverage$1,275100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,275 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$136,038
Medicare patients
226
Services billed
3,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide135$118,927
EliquisApixaban314$115,490
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$61,295
JardianceEmpagliflozin74$59,273
OzempicSemaglutide52$53,710
MyrbetriqMirabegron91$46,511
XareltoRivaroxaban61$38,481
ProliaDenosumab16$28,004
RybelsusSemaglutide26$25,469
Tresiba Flextouch U-100Insulin Degludec92$19,449
VascepaIcosapent Ethyl40$18,984
GemtesaVibegron55$18,257
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$16,034
LinzessLinaclotide17$14,659
MounjaroTirzepatide12$12,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$62$131,291147 claims
PfizerEliquis, Premarin$97$121,131333 claims
Novo NordiskOzempic, Rybelsus$229$79,17978 claims
Boehringer IngelheimJardiance, Combivent Respimat$60$68,54692 claims
GSKTrelegy Ellipta$79$61,29575 claims
Astellas Pharma US IncMyrbetriq$22$46,51191 claims
AstraZenecaBreztri Aerosphere, Farxiga, Brilinta$155$28,38157 claims
AmgenProlia$18$28,00416 claims
AbbVieLinzess, Namzaric$124$23,62931 claims
MerckJanuvia$14$11,15528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Brownwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →